PE20030663A1 - Sal de acido citrico de un compuesto terapeutico y composiciones farmaceuticas que la contienen - Google Patents
Sal de acido citrico de un compuesto terapeutico y composiciones farmaceuticas que la contienenInfo
- Publication number
- PE20030663A1 PE20030663A1 PE2002001163A PE2002001163A PE20030663A1 PE 20030663 A1 PE20030663 A1 PE 20030663A1 PE 2002001163 A PE2002001163 A PE 2002001163A PE 2002001163 A PE2002001163 A PE 2002001163A PE 20030663 A1 PE20030663 A1 PE 20030663A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical compositions
- citric acid
- acid salt
- compositions containing
- therapeutic compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- -1 3,4-DICHLOROPHENYL Chemical class 0.000 abstract 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001860 citric acid derivatives Chemical class 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 238000005388 cross polarization Methods 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
SE REFIERE A SAL CITRATO DE 4-(3,4-DICLOROFENIL)-2-[2-(4-METILPIPERAZIN-1-IL)BENCILIDEN]TIOMORFOLIN-3-ONA DE FORMULA I QUE SE CARACTERIZA POR i)PATRON DE DIFRACCION DE RAYOS X MEDIDO CON RADIACION DE COBRE DE 2 TETA CON UN PICO DE 17,4, 20 Y DE DISTANCIAS INTEBASALES d ENTRE 6,8 A 2,8; ii)REBLANDECIMIENTO Y DESCOMPOSICION COMIENZA DE 198°C A 199°C; iii)AL EXAMINARLO POR TECNICAS DE POLARIZACION CRUZADA CON DESACOPLO DE PROTON DE C(13)NMR EN ESTADO SOLIDO, PRESENTA UN PICO DE RESONANCIA PRINCIPAL DE 179,3; 177,0; 171,6, ENTRE OTROS. EL CITRATO DEL COMPUESTO TIENE PROPIEDADES DE ESTABILIDAD Y COMPATIBILIDAD CON EXCIPIENTES DE LA FORMULACION. EL COMPUESTO ES ANTAGONISTA DEL RECEPTOR 1-D DE SEROTONINA Y PUEDE SER UTIL PARA EL TRATAMIENTO DE HIPERTENSION, DEPRESION EN PACIENTES CON CANCER, PARKINSON, INFARTO DE MIOCARDIO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33834301P | 2001-12-07 | 2001-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030663A1 true PE20030663A1 (es) | 2003-08-04 |
Family
ID=23324428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002001163A PE20030663A1 (es) | 2001-12-07 | 2002-12-03 | Sal de acido citrico de un compuesto terapeutico y composiciones farmaceuticas que la contienen |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6825193B2 (es) |
| EP (1) | EP1451166B1 (es) |
| JP (1) | JP4165882B2 (es) |
| KR (1) | KR100572430B1 (es) |
| CN (1) | CN100358878C (es) |
| AR (1) | AR037711A1 (es) |
| AT (1) | ATE301647T1 (es) |
| AU (1) | AU2002347504B2 (es) |
| BR (1) | BR0214780A (es) |
| CA (1) | CA2469225C (es) |
| DE (1) | DE60205504T2 (es) |
| DK (1) | DK1451166T3 (es) |
| ES (1) | ES2243774T3 (es) |
| GT (1) | GT200200260A (es) |
| HN (1) | HN2002000354A (es) |
| IL (1) | IL162096A0 (es) |
| MX (1) | MXPA04005418A (es) |
| NO (1) | NO327100B1 (es) |
| NZ (1) | NZ532993A (es) |
| PA (1) | PA8560101A1 (es) |
| PE (1) | PE20030663A1 (es) |
| PL (1) | PL370307A1 (es) |
| PT (1) | PT1451166E (es) |
| RU (1) | RU2270834C2 (es) |
| TW (1) | TWI233356B (es) |
| UY (1) | UY27570A1 (es) |
| WO (1) | WO2003048141A1 (es) |
| ZA (1) | ZA200404226B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1746091A1 (en) * | 2001-08-30 | 2007-01-24 | Pfizer Products Inc. | Process for the preparation of 2-substituted 2-[-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one citrate |
| US20050171095A1 (en) * | 2004-01-06 | 2005-08-04 | Pfizer Inc | Combination of CRF antagonists and 5-HT1B receptor antagonists |
| CA2565996A1 (en) * | 2004-05-11 | 2005-11-17 | Pfizer Products Inc. | Combination of atypical antipsychotics and 5-ht1b receptor antagonists |
| WO2005113526A2 (en) * | 2004-05-21 | 2005-12-01 | Pfizer Products Inc. | Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one |
| CA2580034A1 (en) * | 2004-09-10 | 2006-03-16 | Pfizer Products Inc. | Methods of treating mood disorders using benzisoxazole containing diazabicyclic compounds |
| US8080584B2 (en) | 2009-01-23 | 2011-12-20 | Teva Pharmaceuticals Industries, Ltd. | Delayed release rasagiline citrate formulation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| US6423708B1 (en) * | 1996-09-30 | 2002-07-23 | Pfizer Inc | Aralkyl and aralkylidene heterocyclic lactams and imides |
| UA56185C2 (uk) * | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
-
2002
- 2002-11-25 IL IL16209602A patent/IL162096A0/xx unknown
- 2002-11-25 NZ NZ532993A patent/NZ532993A/en unknown
- 2002-11-25 CA CA2469225A patent/CA2469225C/en not_active Expired - Fee Related
- 2002-11-25 AU AU2002347504A patent/AU2002347504B2/en not_active Ceased
- 2002-11-25 RU RU2004117091/04A patent/RU2270834C2/ru not_active IP Right Cessation
- 2002-11-25 JP JP2003549332A patent/JP4165882B2/ja not_active Expired - Fee Related
- 2002-11-25 PT PT02783438T patent/PT1451166E/pt unknown
- 2002-11-25 ES ES02783438T patent/ES2243774T3/es not_active Expired - Lifetime
- 2002-11-25 DE DE60205504T patent/DE60205504T2/de not_active Expired - Lifetime
- 2002-11-25 WO PCT/IB2002/004972 patent/WO2003048141A1/en not_active Ceased
- 2002-11-25 EP EP02783438A patent/EP1451166B1/en not_active Expired - Lifetime
- 2002-11-25 BR BR0214780-7A patent/BR0214780A/pt not_active IP Right Cessation
- 2002-11-25 KR KR1020047008647A patent/KR100572430B1/ko not_active Expired - Fee Related
- 2002-11-25 AT AT02783438T patent/ATE301647T1/de not_active IP Right Cessation
- 2002-11-25 PL PL02370307A patent/PL370307A1/xx not_active Application Discontinuation
- 2002-11-25 DK DK02783438T patent/DK1451166T3/da active
- 2002-11-25 MX MXPA04005418A patent/MXPA04005418A/es active IP Right Grant
- 2002-11-25 CN CNB028243129A patent/CN100358878C/zh not_active Expired - Fee Related
- 2002-12-03 PE PE2002001163A patent/PE20030663A1/es not_active Application Discontinuation
- 2002-12-04 TW TW091135151A patent/TWI233356B/zh not_active IP Right Cessation
- 2002-12-05 HN HN2002000354A patent/HN2002000354A/es unknown
- 2002-12-05 AR ARP020104718A patent/AR037711A1/es unknown
- 2002-12-06 GT GT200200260A patent/GT200200260A/es unknown
- 2002-12-06 UY UY27570A patent/UY27570A1/es not_active Application Discontinuation
- 2002-12-06 US US10/313,467 patent/US6825193B2/en not_active Expired - Fee Related
- 2002-12-06 PA PA20028560101A patent/PA8560101A1/es unknown
-
2004
- 2004-05-28 ZA ZA200404226A patent/ZA200404226B/en unknown
- 2004-07-06 NO NO20042871A patent/NO327100B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5868948B2 (ja) | リジン特異的脱メチル化酵素１阻害薬およびその使用 | |
| JP7026716B2 (ja) | ビグアニド化合物及びその使用 | |
| WO2001087293A1 (en) | -secretase inhibitors | |
| RU2213743C2 (ru) | Производное тиенилазолилалкоксиэтанамина, способ его получения (варианты), фармацевтическая композиция, промежуточный продукт и способ его получения (варианты) | |
| BRPI0519262A2 (pt) | derivados de pirazol fundidos e mÉtodos de tratamento de distérbios metabàlicos-relacionados destes | |
| JP2023175689A (ja) | 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用 | |
| JP2000514060A (ja) | ムスカリン様アンタゴニスト | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| US9376419B2 (en) | Solid forms of nilotinib hydrochloride | |
| TW201311690A (zh) | 抑制暫態受體電位離子通道ｔｒｐａ１ | |
| ES2363366T3 (es) | Derivados sustituidos de carboestirilo como agonistas del subtipo de receptor 5-ht1a para el tratamiento de transtornos bipolares. | |
| GT200000197A (es) | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida. | |
| DE60322680D1 (de) | Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen | |
| SK154996A3 (en) | A compound active as serotonin 5-ht1a and dopamin d2 receptor ligands, pharmaceutical composition and use | |
| CA2494061A1 (en) | Protein tyrosine kinase inhibitors | |
| PE20030663A1 (es) | Sal de acido citrico de un compuesto terapeutico y composiciones farmaceuticas que la contienen | |
| CY1105479T1 (el) | Παραγωγα τετραζολιου και μεθοδοι αντιμετωπισης σχετιζομενων με τον μεταβολισμο διαταραχων με αυτα | |
| DE69207301T2 (de) | Substituierte 3-Piperazinylalkyl 2,3-Dihydro-4H-1,3-Benzoxazin-4-One, deren Herstellung und Verwendung in Heilkunde | |
| TW201641492A (zh) | 經取代1,2,3-三唑、其用途、以及包含其之醫藥組成物 | |
| EP3778586A1 (en) | Quinazoline compound serving as egfr triple mutation inhibitor and applications thereof | |
| JP3857919B2 (ja) | ４−アミノ−６，７−ジメトキシ−２−（５−メタンスルホンアミド−１，２，３，４−テトラヒドロイソキノル−２−イル）−５−（２−ピリジル）キナゾリンメシラートおよび多形 | |
| JPH08283219A (ja) | アラルキルアミノアルキルアミド誘導体 | |
| SK283237B6 (sk) | Pseudopolymorfné formy dihydrochloridu kyseliny 2-[2-[4-[bis(4-fluórfenyl)metyl]-1-piperazinyl]etoxy]octovej, spôsob ich prípravy a farmaceutické kompozície s ich obsahom | |
| EP2199274A1 (en) | Co-crystals of tramadol and paracetamol | |
| US20170015640A1 (en) | Use of arylalkanolamines as sigma-1 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |